Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)
In a report released today, Gena Wang from Barclays maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price ...
Bernstein Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX)
In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...
kffhealthnews17h
Truveta Says It Will Create Huge Archive Of Patients’ Genetic Data
The health data company, based in Bellevue, Washington, plans to collect leftover specimens from consenting patients who get routine health care at participating facilities, Stat reported. Also in the ...
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...
sicklecellanemianews17h
Orna, Vertex partner on gene-editing therapies for SCD, TDT
Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock ...
AMD, Pinterest, and 6 Other Growth Stocks That Look Undervalued
Growth stocks are getting hammered by soaring bond yields. First off, long-dated bond yields have taken a wrecking ball to ...
precisionmedicineonline16h
Intellia Readying for Commercial Activities, First Product Launch in 2027
The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...